Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Ottou
Maraviroc 150 Mg Daily Plus Lopinavir/Ritonavir, a Nucleoside/Nucleotide Reverse Transcriptase Inhibitor-Sparing Regimen for HIV-infected Naive Patients: 48-Week Final Results of VEMAN Study
Clinical Microbiology and Infection
Medicine
Infectious Diseases
Microbiology
Related publications
Efficacy of a Nucleoside-Sparing Regimen of Darunavir/Ritonavir Plus Raltegravir in Treatment-Naive HIV-1-infected Patients (ACTG A5262)
AIDS
Infectious Diseases
Allergy
Immunology
Pharmacokinetics of Etravirine Combined With Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
AIDS Research and Treatment
Immunology
Public Health
Allergy
Environmental
Dermatology
Infectious Diseases
Occupational Health
Multicenter Study of Skin Rashes and Hepatotoxicity in Antiretroviral-Naïve HIV-positive Patients Receiving Non-Nucleoside Reverse-Transcriptase Inhibitor Plus Nucleoside Reverse-Transcriptase Inhibitors in Taiwan
PLoS ONE
Multidisciplinary
HIV-1 Reverse Transcriptase Nucleotide Substitutions in Subtype C–Infected, Drug-Naive, and Treatment-Experienced Patients in South India
Journal of Acquired Immune Deficiency Syndromes
Infectious Diseases
Pharmacology
Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients With Nucleoside Reverse Transcriptase Inhibitor Resistance
AIDS Research and Human Retroviruses
Virology
Infectious Diseases
Immunology
Fosamprenavir or Atazanavir Once Daily Boosted With Ritonavir 100mg, Plus Tenofovir/Emtricitabine, for the Initial Treatment of HIV Infection: 48-Week Results of ALERT
AIDS Research and Therapy
Virology
Molecular Medicine
Pharmacology
Nucleoside Reverse Transcriptase Inhibitor Usage and the Incidence of Peripheral Neuropathy in HIV/AIDS Patients
Antiviral Chemistry and Chemotherapy
Medicine
Virology
Drug Discovery
Pharmacology
96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study
Antiviral Therapy
Infectious Diseases
Pharmacology
Development of a Vaginal Delivery Film Containing EFdA, a Novel Anti-Hiv Nucleoside Reverse Transcriptase Inhibitor
International Journal of Pharmaceutics
Pharmaceutical Science
